Study of vicagrel for heart attack patients getting stents
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new medicine called vicagrel for people who have had a heart attack or unstable angina and are getting a stent. The goal is to see if it works better than standard treatments to prevent future heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been diagnosed with a heart attack or unstable angina and are scheduled to have a stent placed
- You are willing to sign a consent form and follow the study schedule
- You are not expected to live less than 12 months due to other illnesses
- You do not have severe liver disease (for example, cirrhosis or very high liver enzymes)
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a shorter, lower dose of two blood thinners is safe and effective for patients with a recent heart attack or unstable angina who are at high risk for bleeding. It uses a special stent that might allow for less medication.
This trial tests whether a lower dose of the blood thinner ticagrelor works better than clopidogrel in people with stable coronary artery disease who are getting a planned stent. It aims to find which drug is safer and more effective for preventing future heart problems.
This study tests if a single blood thinner (ticagrelor) works well enough after getting a heart stent, instead of the usual two blood thinners. It may simplify your daily medication routine.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
This study compares ticagrelor taken at a lower dose versus regular aspirin to help prevent future heart attacks in people who recently had a stent placed after acute coronary syndrome. You may qualify if you’re considered “high risk” for new blockages or clots and can take dual anti-platelet therapy for 12 months.
This study tests whether taking a single blood-thinning medication (instead of two) after heart stent placement is safe and effective over the long term. If you've recovered well from a stent procedure, this trial may help determine the safest way to prevent future heart problems.
Hear when a new Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.